sorafenib has been researched along with sta 9090 in 1 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (sta 9090) | Trials (sta 9090) | Recent Studies (post-2010) (sta 9090) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 133 | 13 | 129 |
Protein | Taxonomy | sorafenib (IC50) | sta 9090 (IC50) |
---|---|---|---|
Heat shock protein HSP 90-alpha | Homo sapiens (human) | 1.3771 | |
Heat shock protein HSP 90-beta | Homo sapiens (human) | 1.8193 | |
Endoplasmin | Homo sapiens (human) | 0.0377 | |
Endoplasmin | Canis lupus familiaris (dog) | 0.01 | |
Heat shock protein 75 kDa, mitochondrial | Homo sapiens (human) | 0.0444 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Abdel-Reheim, MA; Aboregela, AM; Al-Ameer, AY; Alamri, MMS; Alfaifi, J; Cavalu, S; Hasan, AM; Hashish, AA; Khalid, TBA; Mohammed, OA; Saber, S; Saleh, LA; Senbel, A | 1 |
1 other study(ies) available for sorafenib and sta 9090
Article | Year |
---|---|
Ganetespib (STA-9090) augments sorafenib efficacy via necroptosis induction in hepatocellular carcinoma: Implications from preclinical data for a novel therapeutic approach.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Hypoxia; Liver Neoplasms; Mice; Necroptosis; Sorafenib | 2023 |